Alfred Kim

Dr. Alfred Kim

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRita E. Chen
Rita E. Chen
XZXianwen Zhang
Xianwen Zhang
JCJames Brett Case
James Brett Case
EWEmma S. Winkler
Emma S. Winkler
YLYang Liu
Yang Liu
MDMichael Diamond
Michael Diamond

6 August 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
AJAnuja Java
Anuja Java
AAAnthony J. Apicelli
Anthony J. Apicelli
M. Kathryn LiszewskiM. Kathryn Liszewski
M. Kathryn Liszewski
MMMina Musashi
Mina Musashi
JAJohn P. Atkinson
John P. Atkinson
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19–related morbidity and mortality have been attributed to an exaggerated immune response. The role of complement activation and its contribution to illness severity is being increasingly recognized. Here, we summarize current knowledge about the interaction of coronaviruses with the complement system. We posit that (a) coronaviruses activate multiple complement pathways; (b) severe COVID-19 clinical features often resemble complementopathies; (c) the combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19; (d) a subset of patients with COVID-19 may have a genetic predisposition associated with complement dysregulation; and (e) these observations create a basis for clinical trials of complement inhibitors in life-threatening illness.

1 November 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDParakkal Deepak
Parakkal Deepak
WKWooseob Kim
Wooseob Kim
MPMichael A. Paley
Michael A. Paley
MYMonica Yang
Monica Yang
ACAlexander B. Carvidi
Alexander B. Carvidi
AKAlfred Kim
Alfred Kim
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine ... Visual Effect of Immunosuppression on Immunogenicity of mRNA SARS-CoV-2 Vaccines. Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients ma... Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides ...

28 May 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
LMLina Ma
Lina Ma
SSSanjaya K. Sahu
Sanjaya K. Sahu
MCMarlene Cano
Marlene Cano
VKVasanthan Kuppuswamy
Vasanthan Kuppuswamy
JBJamal Bajwa
Jamal Bajwa
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
Increased complement activation is observed in COVID-19 compared with non-COVID respiratory illness and is a key marker of organ failure.

25 February 2022 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
RGRebecca Grainger
Rebecca Grainger
AKAlfred Kim
Alfred Kim
RCRichard Conway
Richard Conway
JYJinoos Yazdany
Jinoos Yazdany
PRPhilip C. Robinson
Philip C. Robinson

1 February 2014 in Rheumatic Disease Clinics of North America
Verified
Journal Article
Closed access
JMJonathan J. Miner
Jonathan J. Miner
AKAlfred Kim
Alfred Kim